Karyopharm receives conditional marketing authorization in the united kingdom (uk) for nexpovio® (selinexor) in combination with dexamethasone for the treatment of adult patients with relapsed and or refractory multiple myeloma

Newton, mass., june 2, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that on may 26, 2021 the uk's medicines & healthcare products regulatory agency (mhra) granted conditional marketing authorization for nexpovio® (selinexor), the company's first-in-class, oral selective inhibitor of nuclear export (sine) medicine, in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
KPTI Ratings Summary
KPTI Quant Ranking